Drug Type Biosimilar, Monoclonal antibody |
Synonyms Xdivane |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Preclinical | SE | 26 Apr 2024 | |
Head and Neck Neoplasms | Preclinical | SE | 26 Apr 2024 | |
Lung Cancer | Preclinical | SE | 26 Apr 2024 | |
Renal Cell Carcinoma | Preclinical | SE | 26 Apr 2024 | |
Skin Neoplasms | Preclinical | SE | 26 Apr 2024 |